Elacestrant for premenopausal women with early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage I or II breast cancer that is ER-positive and HER2-negative.
- You are premenopausal and still having regular periods or have hormone levels in the premenopausal range.
- You have not had any prior chemotherapy, targeted therapy, or radiation for this breast cancer.
- You are a candidate for primary breast surgery (your doctor plans surgery as the first treatment).
- You are age 18 or older and have good organ function (kidney, liver, blood counts) as shown by recent tests.
- You agree to use effective contraception if you could become pregnant, for the duration of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.